F030 How to Approach Challenges in Hidradenitis Suppurativa Management: Strategies to Optimize Use of HS Therapies
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
This session will provide guidance for the management of hidradenitis suppurativa in challenging scenarios including in the setting of multiple previous treatment failures, pregnancy, and comorbidities such as malignancy and chronic infections. Combination therapy strategies, therapeutic drug monitoring, and flare management will be discussed. Procedures for HS that can be done in the office, and when to reach for them, will be reviewed. Instructive cases of HS will be presented and explored in an interactive format. Practical tips and pertinent evidence from the literature will be discussed to help inform future decision-making in HS clinic visits.
LEARNING OBJECTIVES
Utilize up-to-date evidence to approach challenges in the management of hidradenitis suppurativa, addressing comorbidities, treatment selection, therapeutic drug monitoring, layering therapies, recalcitrant disease, flare management, and pregnancy
Identify helpful combination management strategies in HS
Describe procedures that can be performed in the outpatient setting for patients with HS
SCHEDULE
2:00 PM
HS Procedures: You can do it!
Maria Aleshin, MD, FAAD
2:15 PM
Biologics: how to choose and when to switch
Alexandra P Charrow, MD, FAAD
2:30 PM
Recalcitrant HS - what to do next?
Jennifer Lin Hsiao, MD, FAAD
2:40 PM
HS in the setting of chronic infections and malignancy
Amit Garg, MD, FAAD
2:55 PM
Considering inflammatory comorbidities in HS patients
Noah Goldfarb, MD, FAAD
3:10 PM
HS Flare Management
Vivian Shi, MD, FAAD
3:20 PM
HS and Pregnancy
Katrina Lee, MD, FAAD
3:30 PM
Tips for Managing Pediatric HS
Colleen Cotton, MD, FAAD
3:40 PM
Optimizing the HS visit
Andrea Tesvich Murina, MD, FAAD
3:50 PM
Q&A session
SPEAKERS
Maria Aleshin, MD, FAAD
Alexandra P Charrow, MD, FAAD
Colleen Cotton, MD, FAAD
Amit Garg, MD, FAAD
Noah Goldfarb, MD, FAAD
Jennifer Lin Hsiao, MD, FAAD
Katrina Lee, MD, FAAD
Andrea Tesvich Murina, MD, FAAD
Vivian Shi, MD, FAAD
HANDOUTS
SPEAKER DISCLOSURES
Maria Aleshin, MD, FAAD
Mirador – Consultant (1099 relationship)(No Compensation Received); Novartis – Advisory Board(Fees); Santa Ana Bio – Consultant (1099 relationship)(Fees); UCB – Other(Grants/Research Funding);
Alexandra P Charrow, MD, FAAD
Avalo – Consultant (1099 relationship)(Fees); Dermatology Foundation – Investigator(Grants/Research Funding); Hidradenitis Suppurativa Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Incyte Corporation – Advisory Board(Fees), Investigator(No Compensation Received); Insmed – Investigator(No Compensation Received); Insmed Incorporated – Investigator(No Compensation Received); Novartis Pharmaceuticals Corp. – Advisory Board(Fees); Q32 Bio Inc. – Consultant (1099 relationship)(No Compensation Received); Sonoma Biotherapeutics – Investigator(No Compensation Received); UCB Pharma – Advisory Board(Honoraria); Wedbush Securities – Consultant (1099 relationship)(Honoraria);
Colleen Cotton, MD, FAAD
Amgen – Investigator(Grants/Research Funding); HS Foundation – Board of Directors(No Compensation Received), Investigator(Grants/Research Funding); Inner Archways LLC – Advisory Board(Other Financial Benefit); MoonLake Immunotherapeutics – Investigator(Grants/Research Funding); Pfizer Inc. – Consultant (1099 relationship)(No Compensation Received); Pierre Fabre – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding);
Amit Garg, MD, FAAD
AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Novartis – Consultant(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Sanofi – Data Safety Monitoring Board(Fees); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);
Noah Goldfarb, MD, FAAD
MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Novartis – Investigator(Grants/Research Funding); Sonoma Biotherapeutics – Consultant (1099 relationship)(Fees); UCB – Advisory Board(Fees);
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Novartis – Consultant(Fees), Speaker(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); UCB – Consultant(Fees), Speaker(Fees);
Katrina Lee, MD, FAAD
Incyte – Advisory Board(Fees), Investigator(Grants/Research Funding); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding);
Andrea Tesvich Murina, MD, FAAD
AbbVie – Speaker(Honoraria); Amgen – Speaker(Honoraria); Boehringer Ingelheim – Consultant (1099 relationship)(Honoraria); Botanix Pharmaceuticals – Speaker(Honoraria); Bristol-Myers Squibb – Speaker(Honoraria); Eli Lilly and Company – Speaker(Honoraria); Galderma – Speaker(Honoraria); Janssen Biotech – Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Ortho Dermatologics – Advisory Board(Honoraria), Speaker(Honoraria); Pfizer Inc. – Speaker(Honoraria); Takeda Pharmaceuticals USA Inc – Advisory Board(Honoraria); UCB – Advisory Board(Honoraria); UCB Pharma – Speaker(Honoraria);
Vivian Shi, MD, FAAD
AbbVie – Advisory Board(Fees), Speaker(Fees); Alumis – Advisory Board(Honoraria); Aristea Therapeutics – Advisory Board(Fees); Bain Capital – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Advisory Board(Fees); Burt's Bees – Consultant(Fees); Ceraclere – Consultant (1099 relationship)(Fees); Dematology Foundation – Other(Grants/Research Funding); Demira – Advisory Board(Fees); Dermavant Sciences, Inc. – Advisory Board(Fees); Eli Lilly and Company – Advisory Board(Fees); Foundation of Atopic Dermatitis – Other(Grants/Research Funding); Galderma – Advisory Board(Fees); Genentech, Inc. – Advisory Board(Honoraria); Global Parents for Eczema Research – Consultant(No Compensation Received); GpSkin – Consultant(Fees); HS Foundation – Board of Directors(No Compensation Received); Incyte – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); LearnHealth/LearnSkin – Other(Fees), Stockholder(Stock); Leo Pharma – Consultant (1099 relationship)(Fees); Menlo Therapeutics – Advisory Board(Fees); National Eczema Association – Consultant (1099 relationship)(Honoraria), Speaker(No Compensation Received); Novartis – Advisory Board(Fees); Pfizer Inc. – Advisory Board(Fees); Polyfins, Inc – Consultant (1099 relationship)(Fees); Regeneron – Speaker(Fees); Sanofi Genzyme – Advisory Board(Fees), Speaker(Fees); Skin Actives Scientific – Other(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees); UCB Pharma – Advisory Board(Honoraria);